- Stocks
- Pharma & Healthcare
- Syncom Formulations (India)
Syncom Formulations (India) share price
NSE: SYNCOMFPharma & HealthcareDrug Manufacturers - Specialty & Generic
Syncom Formulations (India) at a glance
Syncom Formulations (India) (NSE: SYNCOMF) closed at ₹22.83 on 22 Oct 2026, up 3.21% on the day. With a market capitalisation of ₹2,146 Cr, it ranks 1116th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 28.2× trailing earnings, against a return on equity of 18.4% in FY26. Over the past year the share price has risen 38.8%. Its 52-week range is ₹10.21 (30 Mar 2026) to ₹27.49 (30 Sep 2026); the last close is 17.0% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹135 Cr (−9.0% year on year) and net profit ₹25 Cr (+42.3%), on a consolidated basis. Promoters held 50.57% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,146 CrRank 1116 on NSE
- P/E (trailing)
- 28.2×
- Price to book
- 2.33×FY26
- EPS (TTM)
- ₹0.89to Q4 FY26
- ROE
- 18.4%FY26
- ROCE
- 23.8%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 15.6%FY26
- Book value / share
- ₹4.41FY26
- 52-week high
- ₹27.4930 Sep 2026
- 52-week low
- ₹10.2130 Mar 2026
- 1-year return
- +38.8%
- RSI (14-day)
- 55.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +3.21% | +1.7% | +15.3% | +72.7% | +38.8% |
Syncom Formulations (India) quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹87 Cr | ₹102 Cr | ₹128 Cr | ₹149 Cr | ₹117 Cr | ₹122 Cr | ₹115 Cr | ₹135 Cr |
| Revenue YoY | +45.8% | +60.3% | +95.8% | +99.7% | +34.0% | +19.0% | −9.7% | −9.0% |
| Net profit | ₹8 Cr | ₹11 Cr | ₹13 Cr | ₹18 Cr | ₹16 Cr | ₹17 Cr | ₹19 Cr | ₹25 Cr |
| Net profit YoY | +73.4% | +70.7% | +85.7% | +139.1% | +106.4% | +49.4% | +45.5% | +42.3% |
| Net margin | 8.7% | 10.9% | 10.2% | 11.9% | 13.5% | 13.6% | 16.4% | 18.6% |
| EPS | ₹0.11 | ₹0.16 | ₹0.14 | ₹0.16 | ₹0.21 | ₹0.18 | ₹0.23 | ₹0.27 |
Syncom Formulations (India) financials
| Item | FY17 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹185 Cr | ₹220 Cr | ₹224 Cr | ₹263 Cr | ₹465 Cr | — |
| Operating profit | ₹16 Cr | ₹26 Cr | ₹27 Cr | ₹34 Cr | ₹66 Cr | — |
| Net profit | ₹11 Cr | ₹20 Cr | ₹20 Cr | ₹25 Cr | ₹49 Cr | — |
| EPS (₹) | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹1.00 | — |
| Cash from operations | ₹14 Cr | ₹16 Cr | ₹11 Cr | −₹6 Cr | ₹23 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹117 Cr | ₹222 Cr | ₹256 Cr | ₹288 Cr | ₹342 Cr | ₹415 Cr |
Syncom Formulations (India) shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% |
| Foreign institutions | 0.11% | 0.41% | 0.10% | 0.26% | 0.21% | 0.35% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 49.32% | 49.02% | 49.33% | 49.17% | 49.21% | 49.08% |
Syncom Formulations (India) vs peers
The listed Pharma & Healthcare companies nearest to Syncom Formulations (India) by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| DCALDishman Carbogen Amcis | ₹141.95 | +0.07% | −49.1% | ₹2,226 Cr | 22.8 | — |
| VIMTALABSVimta Labs | ₹495.55 | +2.15% | −28.3% | ₹2,214 Cr | 28.5 | — |
| MEDIASSISTMedi Assist Healthcare Services | ₹291.75 | −0.61% | −46.7% | ₹2,179 Cr | 24.1 | — |
| SYNCOMFSyncom Formulations (India) | ₹22.83 | +3.21% | +38.8% | ₹2,146 Cr | 28.2 | — |
| INDOCOIndoco Remedies | ₹230.55 | +0.74% | −21.9% | ₹2,128 Cr | — | — |
| PANACEABIOPanacea Biotec | ₹335.85 | −1.22% | −24.2% | ₹2,057 Cr | — | — |
| SAKARSakar Healthcare | ₹923.90 | +2.66% | +156.4% | ₹2,056 Cr | 67.6 | — |
Ask anything about Syncom Formulations (India)
Pivot answers on the live chart with evidence you can check, and tests strategies against SYNCOMF's own history. Try: “Why has SYNCOMF moved over the last three months?” · “Backtest a 50-day moving-average crossover on SYNCOMF over five years” · “Compare SYNCOMF with DCAL on margins and valuation”
Frequently asked questions about Syncom Formulations (India)
What is the share price of Syncom Formulations (India) today?
Syncom Formulations (India) (NSE: SYNCOMF) last closed at ₹22.83 on 22 Oct 2026. Its 52-week high is ₹27.49 and its 52-week low is ₹10.21.
What is the market cap of Syncom Formulations (India)?
Syncom Formulations (India)'s market capitalisation is ₹2,146 Cr (₹2,146 Cr) at the 22 Oct 2026 close, ranking 1116th among the NSE companies Pivot tracks.
What is the P/E ratio of Syncom Formulations (India)?
Syncom Formulations (India) trades at a trailing P/E of 28.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 28.5.
What is the ROE and ROCE of Syncom Formulations (India)?
Return on equity was 18.4% in FY26 and return on capital employed was 23.8% in FY26 (consolidated figures).
Is Syncom Formulations (India) a debt-free company?
Syncom Formulations (India) is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Syncom Formulations (India)'s latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Syncom Formulations (India) reported revenue of ₹135 Cr, −9.0% year on year, and net profit of ₹25 Cr, +42.3% year on year.
How has Syncom Formulations (India) stock performed over the last year?
Syncom Formulations (India)'s share price has risen 38.8% over the past year, +72.7% over three months and +15.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Syncom Formulations (India)?
As of 30 Jun 2026: promoters 50.57%, foreign institutions 0.35%, domestic institutions 0.00%, non-institutions 49.08%.
Who are Syncom Formulations (India)'s competitors?
The listed Pharma & Healthcare companies closest to Syncom Formulations (India) by market cap are Dishman Carbogen Amcis, Vimta Labs, Medi Assist Healthcare Services, Indoco Remedies, Panacea Biotec and Sakar Healthcare.
Is Syncom Formulations (India) a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Syncom Formulations (India)'s price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SYNCOMF against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text